US2003031682A1PendingUtilityA1

Novel group b streptococcus antigens

31
Priority: Feb 20, 1998Filed: Feb 18, 1999Published: Feb 13, 2003
Est. expiryFeb 20, 2018(expired)· nominal 20-yr term from priority
Inventors:Bernard R. BrodeurClement RiouxMartine BoyerIsabelle CharleboisJosee HamelDenis Martin
A61P 37/04A61P 31/04C07K 14/315A61K 39/00C07K 14/00
31
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . An isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide having a sequence selected from the group consisting of: 
 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.    
     
     
         2 . A polynucleotide according to  claim 1 , wherein said polynucleotide encodes a polypeptide having at least 95% identity to the second polypeptide.  
     
     
         3 . An isolated polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence selected from the group consisting of: 
 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.    
     
     
         4 . An isolated polynucleotide that is complementary to the polynucleotide of  claim 1 .  
     
     
         5 . An isolated polynucleotide that is complementary to the polynucleotide of  claim 3 .  
     
     
         6 . The polynucleotide of  claim 1 , wherein said polynucleotide is DNA.  
     
     
         7 . The polynucleotide of  claim 3 , wherein said polynucleotide is DNA.  
     
     
         8 . The polynucleotide of  claim 1 , wherein said polynucleotide is RNA.  
     
     
         9 . The polynucleotide of  claim 3 , wherein said polynucleotide is RNA.  
     
     
         10 . A polynucleotide which hybridizes under stringent conditions to a second polynucleotide having a sequence selected from the group consisting of: 
 SEQ ID NO: 1, SEQ ID NO: 7 SEQ ID NO: 13, SEQ ID NO: 22, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 42 and SEQ ID NO: 43 or fragments, analogues or derivatives thereof.    
     
     
         11 . A polynucleotide which hybridizes under stringent conditions to a second polynucleotide having a sequence selected from the group consisting of: 
 SEQ ID NO: 37, SEQ ID NO: 42 and SEQ ID NO: 43.    
     
     
         12 . A polynucleotide according to  claim 11  which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO: 37.  
     
     
         13 . A polynucleotide according to  claim 11  which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO: 42.  
     
     
         14 . A polynucleotide according to  claim 11  which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO: 43.  
     
     
         15 . A polynucleotide according to  claim 10  wherein said polynucleotide has at least 95% complementarity to the second polynucleotide.  
     
     
         16 . A polynucleotide according to  claim 11  wherein said polynucleotide has at least 95% complementarity to the second polynucleotide.  
     
     
         17 . A vector comprising the polynucleotide of  claim 1 , wherein said polynucleotide is operably linked to an expression control region.  
     
     
         18 . A vector comprising the polynucleotide of  claim 3 , wherein said polynucleotide is operably linked to an expression control region.  
     
     
         19 . A host cell transfected with the vector of  claim 17 .  
     
     
         20 . A host cell transfected with the vector of  claim 18 .  
     
     
         21 . A process for producing a polypeptide comprising culturing a host cell according to  claim 19  under conditions suitable for expression of said polypeptide.  
     
     
         22 . A process for producing a polypeptide comprising culturing a host cell according to  claim 20  under condition suitable for expression of said polypeptide.  
     
     
         23 . An isolated polypeptide having at least 70% identity to a second polypeptide having a sequence selected from the group consisting of: 
 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.    
     
     
         24 . The isolated polypeptide of  claim 23  having a sequence according to SEQ ID NO: 39.  
     
     
         25 . The isolated polypeptide of  claim 23  having a sequence according to SEQ ID NO: 44.  
     
     
         26 . An isolated polypeptide capable of generating antibodies having binding specificity for a second polypeptide having a sequence selected from the group consisting of: 
 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.    
     
     
         27 . The isolated polypeptide of  claim 26  having a sequence according to SEQ ID NO: 39.  
     
     
         28 . The isolated polypeptide of  claim 26  having a sequence according to SEQ ID NO: 44.  
     
     
         29 . An isolated polypeptide having an amino acid sequence selected from the group consisting of: 
 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40 and SEQ ID NO:41 or fragments, analogs or derivatives thereof.    
     
     
         30 . The isolated polypeptide of  claim 29  having an amino acid sequence according to SEQ ID NO: 39.  
     
     
         31 . An isolated polypeptide having an amino acid sequence according to SEQ ID NO: 44.  
     
     
         32 . An isolated polypeptide according to any one of  claims 29  to  31 , wherein the N-terminal Met residue is deleted.  
     
     
         33 . An isolated polypeptide according to any one of  claims 29  to  30 , wherein the secretory amino acid sequence is deleted.  
     
     
         34 . A vaccine composition comprising a polypeptide according to any one of  claims 23  to  31  and a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         35 . A vaccine composition comprising a polypeptide according to  claim 32  and a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         36 . A vaccine composition comprising a polypeptide according to  claim 33  and a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         37 . A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to  claim 34 .  
     
     
         38 . A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to  claim 35 .  
     
     
         39 . A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to  claim 36 .  
     
     
         40 . A method according to any one of  claims 37  to  39 , wherein said animal is a bovine.  
     
     
         41 . A method according to any one of  claims 37  to  39 , wherein said animal is a human.  
     
     
         42 . A method according to any one of  claims 37  to  39 , wherein said bacterial infection is selected from the group consisting of group A streptococcus and group B streptococcus.  
     
     
         43 . A method according to  claim 42 , wherein said bacterial infection is group B streptococcus.

Join the waitlist — get patent alerts

Track US2003031682A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.